Analystreport

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating.

Dicerna Pharmaceuticals, Inc.  (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com